Eversept Partners LP Makes New $1.18 Million Investment in Immunocore Holdings PLC Sponsored ADR $IMCR

Eversept Partners LP purchased a new position in shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) in the first quarter, according to its most recent disclosure with the SEC. The firm purchased 39,238 shares of the company’s stock, valued at approximately $1,183,000.

Other institutional investors have also made changes to their positions in the company. Leonteq Securities AG acquired a new position in Immunocore in the fourth quarter worth approximately $30,000. Harbour Investments Inc. raised its position in Immunocore by 60.2% during the fourth quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock valued at $36,000 after acquiring an additional 388 shares in the last quarter. Rockefeller Capital Management L.P. acquired a new stake in Immunocore in the fourth quarter valued at approximately $47,000. Arax Advisory Partners lifted its stake in Immunocore by 302.9% in the fourth quarter. Arax Advisory Partners now owns 1,386 shares of the company’s stock valued at $48,000 after acquiring an additional 1,042 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Immunocore by 37.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock worth $74,000 after acquiring an additional 572 shares in the last quarter. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently commented on IMCR. Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a research note on Monday, July 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Immunocore in a research note on Friday, July 17th. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a report on Monday, April 20th. Wall Street Zen downgraded shares of Immunocore from a “buy” rating to a “hold” rating in a research report on Tuesday. Finally, Zacks Research lowered Immunocore from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 7th. Five equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $56.71.

Immunocore Trading Down 3.5%

Shares of IMCR stock opened at $33.77 on Tuesday. Immunocore Holdings PLC Sponsored ADR has a 12 month low of $27.56 and a 12 month high of $40.71. The company has a quick ratio of 4.15, a current ratio of 4.18 and a debt-to-equity ratio of 1.00. The business’s 50 day moving average is $30.84 and its two-hundred day moving average is $31.30. The company has a market cap of $1.72 billion, a PE ratio of -61.40 and a beta of 0.73.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.51. The business had revenue of $106.68 million during the quarter, compared to analysts’ expectations of $145.20 million. Immunocore had a negative net margin of 6.68% and a negative return on equity of 7.07%. Immunocore’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.10 earnings per share. Equities analysts predict that Immunocore Holdings PLC Sponsored ADR will post 0.06 EPS for the current year.

Immunocore Company Profile

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.